sinomenine and Shock--Septic

Sinomenine (1) is clinically available for the treatment of rheumatoid arthritis (RA), however, its efficacy is quite weak. In the present study, a library of novel sinomenine-based homodimers and monomers through variable-length linkers were designed and synthesized, and their bioactivities were evaluated using RAW264.7 cells and mice. Among the compounds, 2f and 3b possessed much more potent inhibitory effects on the production of nitric oxide (NO), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) than 1. Preliminary mechanism investigation revealed that 3b inhibited nuclear factor-κB (NF-κB) signaling pathway specifically, 2f suppressed both NF-κB and mitogen-activated protein kinase (MAPK) cascades. Moreover, 3b and 2f significantly alleviated the lipopolysaccharide (LPS)-induced mortality. These two compounds might serve as valuable candidates for anti-inflammatory drug discovery.

Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Cell Proliferation; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Morphinans; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Shock, Septic; Signal Transduction; Tumor Necrosis Factor-alpha